|
Showing 1 - 8 of
8 matches in All Departments
The focus of the 22nd Annual Detroit Cancer Symposium was the
presentation and discussion of cytotoxic agents, with a significant
portion of the symposium including the exciting frontiers of drug
discovery being explored by the National Cooperative Drug Discovery
Groups (NCDDG) Program. The symposium brought together a large
number of investigators from government, universities and
pharmaceutical companies involved in the discovery and development
of new anticancer agents. Exciting new leads were presented and the
status of others presently under development was discussed. Of
particular significance has been the initiation of renewed efforts
in the area of natural product drug discovery, where the discovery
of new cytotoxics is very promising at the moment. A number of
major changes have occurred during the last decade in research on
drug discovery of cytotoxic agents. Critical reviews of a number of
the models and concepts underlying drug discovery represented a
continuous thread throughout the meeting, being constantly
discussed in terms of their advantages, disadvantages and
capabilities of discovering solid tumor active anticancer agents. A
recent development which is to be much applauded and which portends
to great discoveries is the new relationship formed between
Government, University of Industry. The NCDDG mechanism which
stimulates this interaction is an inexpensive manner to greatly
magnify the drug discovery and development effort nationally.
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery
and Development represents a forum which will become the major mode
for bringing together these three different components in the
equation to regularly discuss new results and ideas.
With the publication of these proceedings from the Second Drug
Discovery and Development Symposium, this forum has become the main
mechanism for bringing together the principal groups involved in
both discovering and developing new approaches to the treatment of
cancer. This Second Symposium emphasized the types of materials
being discovered and their therapeutic activity. This is especially
evident in the natural product discovery programs, where unique and
active structures are being identified. The major contributors to
the meeting were the investigators participating in the National
Cooperative (Natural Products) Drug Discovery Groups [NC(NP)DDG].
These groups reflect an association among researchers at
universities or cancer centers, pharmaceutical companies and the
National Cancer Institute. Their sources of materials are varied,
reflecting chemical inventories of pharmaceutical companies,
organic synthetic compounds from the laboratory, cytotoxics as well
as biologics and their hybrids, and natural products obtained from
plants, marine organisms and microorganisms. The models employed in
the discovery systems vary from broadly cellular based to specific
enzymes to defined cellular functions. Each of them is believed
important to the malignant state and will allow for the discovery
of compounds which will have efficacy in cancer therapy. The goal
of the participants is both to discover new anticancer agents and
to develop them as efficiently as possible into clinically useful
additions to treatment. Of importance is the fact that there are a
number of promising leads which will soon be moving into the clinic
thereby testing the effectiveness of this NC (NP) DDG approach.
Where do you begin to look for a recent, authoritative article on
the diagnosis or management of a particular malignancy? The few
general oncology textbooks are generally out of date. Single papers
in specialized journals are informative but seldom comprehensive;
these are more often preliminary reports on a very limited number
of patients. Certain general journals frequently publish good
indepth reviews of cancer topics, and published symposium lectures
are often the best overviews available. Unfortunately, these
reviews and supplements appear sporadically, and the reader can
never be sure when a topic of special interest will be covered.
Cancer treatment and Research is a series of authoritative volumes
which aim to meet this need. It is an attempt to establish a
critical mass of oncology literature covering virtually all
oncology topics, revised frequently to keep the coverage up to
date, easily available on a single library shelf or by a single
personal subscription. We have approached the problem in the
following fashion. First, by dividing the oncology literature into
specific subdivisions such as lung cancer, genitour inary cancer,
pediatric oncology, etc. Second, by asking eminent authorities in
each of these areas to edit a volume on the specific topic on an
annual or biannual basis. Each topic and tumor type is covered in a
volume appearing frequently and predictably, discussing current
diagnosis, staging, markers, all forms of treatment modalities,
basic biology, and more."
Over the past decade, techniques have been developed and
implemented to observe metabolism noninvasively in localized
regions of intact, living experimental animals and humans through
the use of magnetic resonance spectroscopy (MRS). At the same time,
magnetic resonance imaging (MRI) techniques developed in the 1970s
and refined in this decade have been increasingly applied as a
powerful clinical tool to probe human anatomy. Because of the
unusual metabolic and physiologic characteristics of malignant
tissues, oncology has been one of the primary focuses of the
application of both MRS and MRI. Although considerable progress has
been made in oncologic applications of magnetic resonance (MR),
further research is needed to realize the full potential of MR in
this area. Consequently, the 21st Annual Detroit Cancer Symposium
entitled "Magnetic Resonance in Experimental and Clin ical
Oncology" was organized to provide a forum for researchers in the
field to report the state of the art of MRS and MRI in oncol ogy,
to discuss future goals for MRS and MRI in oncology, and to define
the research needed to meet those goals. The major emphasis of the
symposium was on MRS due to both the recent widespread availability
of clinical MRS instrumentation and the extensive amount of animal
MRS research performed over the past half decade.
With the publication of these proceedings from the Second Drug
Discovery and Development Symposium, this forum has become the main
mechanism for bringing together the principal groups involved in
both discovering and developing new approaches to the treatment of
cancer. This Second Symposium emphasized the types of materials
being discovered and their therapeutic activity. This is especially
evident in the natural product discovery programs, where unique and
active structures are being identified. The major contributors to
the meeting were the investigators participating in the National
Cooperative (Natural Products) Drug Discovery Groups [NC(NP)DDG].
These groups reflect an association among researchers at
universities or cancer centers, pharmaceutical companies and the
National Cancer Institute. Their sources of materials are varied,
reflecting chemical inventories of pharmaceutical companies,
organic synthetic compounds from the laboratory, cytotoxics as well
as biologics and their hybrids, and natural products obtained from
plants, marine organisms and microorganisms. The models employed in
the discovery systems vary from broadly cellular based to specific
enzymes to defined cellular functions. Each of them is believed
important to the malignant state and will allow for the discovery
of compounds which will have efficacy in cancer therapy. The goal
of the participants is both to discover new anticancer agents and
to develop them as efficiently as possible into clinically useful
additions to treatment. Of importance is the fact that there are a
number of promising leads which will soon be moving into the clinic
thereby testing the effectiveness of this NC (NP) DDG approach.
The focus of the 22nd Annual Detroit Cancer Symposium was the
presentation and discussion of cytotoxic agents, with a significant
portion of the symposium including the exciting frontiers of drug
discovery being explored by the National Cooperative Drug Discovery
Groups (NCDDG) Program. The symposium brought together a large
number of investigators from government, universities and
pharmaceutical companies involved in the discovery and development
of new anticancer agents. Exciting new leads were presented and the
status of others presently under development was discussed. Of
particular significance has been the initiation of renewed efforts
in the area of natural product drug discovery, where the discovery
of new cytotoxics is very promising at the moment. A number of
major changes have occurred during the last decade in research on
drug discovery of cytotoxic agents. Critical reviews of a number of
the models and concepts underlying drug discovery represented a
continuous thread throughout the meeting, being constantly
discussed in terms of their advantages, disadvantages and
capabilities of discovering solid tumor active anticancer agents. A
recent development which is to be much applauded and which portends
to great discoveries is the new relationship formed between
Government, University of Industry. The NCDDG mechanism which
stimulates this interaction is an inexpensive manner to greatly
magnify the drug discovery and development effort nationally.
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery
and Development represents a forum which will become the major mode
for bringing together these three different components in the
equation to regularly discuss new results and ideas.
Over the past decade, techniques have been developed and
implemented to observe metabolism noninvasively in localized
regions of intact, living experimental animals and humans through
the use of magnetic resonance spectroscopy (MRS). At the same time,
magnetic resonance imaging (MRI) techniques developed in the 1970s
and refined in this decade have been increasingly applied as a
powerful clinical tool to probe human anatomy. Because of the
unusual metabolic and physiologic characteristics of malignant
tissues, oncology has been one of the primary focuses of the
application of both MRS and MRI. Although considerable progress has
been made in oncologic applications of magnetic resonance (MR),
further research is needed to realize the full potential of MR in
this area. Consequently, the 21st Annual Detroit Cancer Symposium
entitled "Magnetic Resonance in Experimental and Clin ical
Oncology" was organized to provide a forum for researchers in the
field to report the state of the art of MRS and MRI in oncol ogy,
to discuss future goals for MRS and MRI in oncology, and to define
the research needed to meet those goals. The major emphasis of the
symposium was on MRS due to both the recent widespread availability
of clinical MRS instrumentation and the extensive amount of animal
MRS research performed over the past half decade."
Where do you begin to look for a recent, authoritative article on
the diagnosis or management of a particular malignancy? The few
general oncology textbooks are generally out of date. Single papers
in specialized journals are informative but seldom comprehensive;
these are more often preliminary reports on a very limited number
of patients. Certain general journals frequently publish good
indepth reviews of cancer topics, and published symposium lectures
are often the best overviews available. Unfortunately, these
reviews and supplements appear sporadically, and the reader can
never be sure when a topic of special interest will be covered.
Cancer treatment and Research is a series of authoritative volumes
which aim to meet this need. It is an attempt to establish a
critical mass of oncology literature covering virtually all
oncology topics, revised frequently to keep the coverage up to
date, easily available on a single library shelf or by a single
personal subscription. We have approached the problem in the
following fashion. First, by dividing the oncology literature into
specific subdivisions such as lung cancer, genitour inary cancer,
pediatric oncology, etc. Second, by asking eminent authorities in
each of these areas to edit a volume on the specific topic on an
annual or biannual basis. Each topic and tumor type is covered in a
volume appearing frequently and predictably, discussing current
diagnosis, staging, markers, all forms of treatment modalities,
basic biology, and more."
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Hampstead
Diane Keaton, Brendan Gleeson, …
DVD
R66
Discovery Miles 660
|